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The prostaglandins are a series of fatty acid
derivatives with numerous biological actions. This
article will review the evidence that certain prosta-
glandins (PG) may play a role in altering renal blood
flow (RBF).
Historical perspective
Although the prostaglandins have been recog-
nized for approximately 45 years [11 and it has been
known for approximately 15 years that they are
produced in the kidney [21, it was only when they
were able to be synthetized in sufficient quantities
to be administered to animals and man that their
biological functions could begin to be evaluated.
Early studies demonstrated that PGA and PGE1 can
dilate many vascular beds, in particular the renal
vascular bed [3, 4]. But, because the amount of
PGE1 relative to the amount of PGE2 is extremely
small [5], it is not clear that such experiments
demonstrate a potential in vivo physiologic role for
prostaglandin E1 to affect RBF. Similarly, because
PGA may not exist in vivo in concentrations that
are detectable at present [6], the potential impor-
tance of the effect of PGA as a renal vasodilator is
also open to question.
Present evidence suggests that the majority of the
prostaglandins produced by mammals in vivo de-
rive from arachidonic acid and thus belong to the
two series. In the past several years, many of these
compounds have been synthesized and thus have
been available for experimental studies.
Direct intrarenal administration
The first line of evidence that prostaglandins
might regulate renal vascular resistance derives
from studies of direct intrarenal administration.
When studies have been performed in which PGE2
[71 and PGD2 [8] have been given directly into the
renal artery of the dog, both of these pro stagiandins
have been found to produce dose-related increases
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in RBF (Fig. I). In contrast, PGF2a has little affect
on renal vascular resistance [9]. PGI2 is also a
potent renal vasodilator [101, whereas thromboxane
A2 [11] and analogs of the endoperoxides [12]
appear to be vasoconstricting agents. The majority
of studies designed to evaluate the role of experi-
mental agents (including prostaglandins) in deter-
mining alterations in renal vascular resistance have
been performed in the dog. This is because the
anatomy of the dog allows for relatively direct
intrarenal administration. Because of some differ-
ences between studies in dogs and rats, the issue of
species variation will be addressed subsequently.
In addition, because the amount of prostaglan-
dins administered into the renal artery has been
large compared with the concentration of measured
prostaglandins in blood, it is not clear that the rate
of prostagiandin administration has been at all com-
parable to that which might occur under physiologic
circumstances. The usual lowest dose studied is
approximately iO g/kg/min (Fig. 1). This dose in a
normal 20-kg dog with a RBF of 200 mi/mm would
lead to a plasma concentration of approximately 100
pg/mi (—280 pmoies/iiter). This is in contrast to the
recent measurements of plasma levels of prosta-
giandin E2, which are approximately 20 pg/mi (—50
pmoles/liter) [131. At the lower dosages of PGE2,
PGD2, and PGI2, the alterations in blood flow are
quite small. Thus, it is possible that the amount of
these hormones in circulating blood is not of suffi-
cient concentration to regularly affect RBF. Of
course, this does not preclude the possibility of
local production and blood flow regulation. In addi-
tion, because the blood levels of PGI2 are difficult
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PGD lowing the administration of indomethacin or me-2
clofenamate [16, 171. These studies have been inter-
preted to support a role for the renal prostaglandins
in vasodilating the kidney under normal conditions.
Similar results have been reported [181, in fewer
studies, in the rat. But, when more recent studies
were performed in which chronically instrumented
awake animals were given indomethacin or RO 20-
5720, smaller or no change in RBF was observed
[19, 201. These studies might best be interpreted to
suggest that during anesthesia, and particularly
following surgery, the prostaglandins do play a role
in vasodilating the renal vasculature. Under the
chronically instrumented awake situation, howev-
er, there is no tonic control of the pros taglandins on
RBF. Alternatively, because most of the nonsteroi-
dal antiinfiammatory agents have effects other than
inhibiting cyclooxygenase, it is possible that some
other consequence of these drugs is responsible for
the alterations in RBF described.
Renal autoregulation
Early studies in which nonsteroidal antiinflamma-
tory drugs were administered to a perfused kidney
preparation suggested that a renal prostaglandin
might play an important role in the autoregulation of
RBF [211. But, when more extensive studies were
performed in both anesthetized dogs and isolated
perfused kidney preparations, autoregulation ap-
peared to be intact both before and following the
administration of nonsteroidal antiinfiammatory
drugs 1122, 23]. Assuming that the concentration of
these agents administered in the latter studies was
sufficient to block a large fraction of ongoing prosta-
glandin synthesis, it would appear to be safe to
conclude that autoregulation of RBF was not solely
dependent on prostaglandin synthesis.
Mechanism of action
Because the rate of alteration in RBF following
prostaglandin administration is quite rapid, it seems
most likely that the prostaglandins interact with
relatively specific receptors on the surface of cells,
presumably smooth muscle cells, involved in the
regulation of vascular resistance. Although PG re-
ceptors have been described in a number of tissues,
very limited studies to date have attempted to
characterize PG receptors in kidney tissue [241.
Once the prostaglandin binds to its receptor site,
there may well be a second messenger involved in
transmitting the signal intracellularly. The vasodila-
tory prostaglandins have been shown to stimulate
cyclic AMP production 11251, and it may be that this
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Fig. 1. Dose-response relationship between intrarenal prosta-
glandin administration and renal blood flow. (Data are redrawn
from Refs. 10, 42, and 43.)
to determine, its possible role as a circulating renal
vasodilator is difficult to evaluate at present.
Redistribution of renal blood flow
In addition to producing increases in total RBF,
PGE2, PGD2, and PGI2 lead to a redistribution of
RBF [8, 101. There is, however, some question at
present whether alterations in RBF distribution
have significant physiologic consequences [14].
Studies with arachidonic acid
The second line of evidence supporting the con-
cept that the renal prostaglandins play a role in
regulating RBF derives from studies with arachi-
donic acid administration. Arachidonic acid is the
fatty acid from which the prostaglandins of the two
series are derived. When arachidonic acid was
administered into the renal artery of the dog, there
was a significant increase in RBF. This increase in
RBF could be blocked by prior treatment of the
animal with an inhibitor of prostaglandin synthesis
[15].
Studies with inhibitors of prostaglandin synthesis
A third line of evidence supporting the suggestion
that the prostaglandins play a role in regulating RBF
derives from studies in which inhibitors of prosta-
glandin synthesis have been administered. There
are presently a large series of nonsteroidal antiin-
flammatory drugs that inhibit cyclooxygenase and
subsequent prostaglandin synthesis. A number of
studies have been performed with one or more non-
steroidal antiinflammatory drugs. In particular, in-
domethacin and meclofenamate have been given to
anesthetized dogs. In the large majority of these
studies, there has been a demonstrable decrease in
RBF and increase in renal vascular resistance fol-
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is the mechanism whereby vasodilatation is
achieved. It is also possible that these prostaglan-
dins alter transcellular calcium transport, and this is
also a possible intracellular mechanism of action
[261. Other possibilities can be suggested as well
[27], but there are little data to bear on this issue at
present.
Modulating role of the renal prostaglandins
Rather than suggesting a primary role for the
renal prostaglandins in regulating RBF, more recent
studies have raised the possibility that the prosta-
glandins might function in a modulating manner to
attenuate the vasoconstricting effects of both angio-
tensin and norepinephrine [28, 29]. This suggestion
is supported by data demonstrating that angiotensin
II (All) is capable of stimulating or augmenting
prostaglandin synthesis [30]. In addition, there is an
increased sensitivity to exogenous All or norepi-
nephrine following the administration of drugs that
inhibit prostaglandin synthesis. This latter observa-
tion has been found in a number of species [18, 311,
including man [321.
Prostaglandins as mediators of vasodilatation
Bradykinin is a potent renal vasodilating agent
and also stimulates prostaglandin synthesis [33].
Although studies have been presented that support
the suggestion that bradykinin-related vasodilata-
tion is prostaglandin mediated [33], this issue is
controversial [341.
Similarly, it has been suggested that the vasodi-
lating effects of other agents, including loop diuret-
ics, are, in part, prostaglandin mediated [35].
Species variability of prostaglandin response
The above discussion has, in large part, referred
to studies performed in the dog. As indicated,
PGE2, PGD2, and P012 are potent renal vasodila-
tors in the dog. PGE2 is also an effective renal
vasodilator in the rabbit [36]. When POE2 was given
to rats, however, several investigators demonstrat-
ed an increase in renal vascular resistance and a
decrease in RBF [36, 37]. There are several possible
explanations for these results: (a) There may be
different receptors, with different physiologic con-
sequences, for PGE2 between the rat and other
species. Consistent with this suggestion are some
recent unpublished observations by Hollenberg
showing a direct effect of PGE2, and other prosta-
glandins, to reduce the size of isolated glomeruli
in vitro. Thus, in fact, it may be that PGE2 is a
direct renal vasoconstrictor in the rat. (b) It is
possible that under most experimental circum-
stances, for some reason, the rat renal vasculature
is normally maximally vasodilated. Thus, when one
performs any maneuver, including giving PGE2, the
only consequence that can be observed is either no
change or a decrease in RBF. But, because PGI2
can dilate the renal vasculature of the rat under
circumstances when PGE2 constricts, maximal
vasodilitation is an untenable hypothesis [37]. (c) A
third possibility is that PGE2 is directly vasodilatory
in the rat, but because of secondary effects of PGE2
administration the overall effect is renal vasocon-
striction with a decrease in RBF. Several lines of
evidence would suggest that this latter possibility
may, in fact, be true: (1) It is well known that PGE2
and PGI2 can stimulate renin release [38]. Although
there was some question as to whether this could
occur in kidney slices [39], relatively recent studies
have demonstrated that PGE2 can stimulate renin
release in kidney slices in vitro as well [40]. Thus, it
is possible that POE2 administration to the rat leads
to sufficient renin release and activation of the
renin-angiotensin system to lead to an increase in
renal vascular resistance and an observed decrease
in RBF. A recent set of studies have observed
changes consistent with this suggestion. Schor,
Ichikawa, and Brenner [41] demonstrated that
glomerular plasma flow fell during PG administra-
tion and that following the administration of a
competitive antagonist of All, saralasin, there was
a highly consistent increase in glomerular plasma
flow. Thus, in these studies, in whole rats, prosta-
glandins presumably augmented renin release and
All generation. The overall result appeared to be an
All-mediated effect that could be blocked by com-
petitive antagonists of All. Thus, it is possible that
in studies in whole rats, PGE2 might activate the
renin-angiotensin system to the extent that the
overall consequence is a decrease in RBF and an
increase in renal vascular resistance. This does not
then necessarily imply that the direct consequences
of POE2 on the renal vasculature of the rat are
different from those in other species.
Summary
Data have been reviewed demonstrating that
PGE2, POD2, and PGI2, all of which are produced
within the kidney, are direct renal vasodilators
when administered to most species. It is possible
that one role for these renal vasodilators is to
maintain RBF during the stress of acute trauma or
surgery. Indeed, prostaglandins may function more
as modulators of vasoconstricting actions or media-
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tors of vasodilating actions of other hormones than
as direct renal vasodilators themselves.
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